Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

por Riancho, Javier, Setien, Sonia, Sánchez de la Torre, Jose Ramón, Torres-Barquin, Marta, Misiego, Mercedes, Pérez, José Luis, Castillo-Triviño, Tamara, Menéndez-García, Cristina, Delgado-Alvarado, Manuel
Publicado 2021

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

por Santiago-Setien, Pilar, Barquín-Rego, Cristina, Hernández-Martínez, Paula, Ezquerra-Marigomez, María, Torres-Barquin, Marta, Menéndez-Garcia, Cristina, Uriarte, Fernando, Jiménez-López, Yésica, Misiego, Mercedes, Sánchez de la Torre, Jose Ramón, Setien, Sonia, Delgado-Alvarado, Manuel, Riancho, Javier
Publicado 2023